ERK activation induced by selenium treatment significantly downregulates β/γ-secretase activity and Tau phosphorylation in the transgenic rat overexpressing human selenoprotein M

International Journal of Molecular Medicine

Volumn 24, Issue 1, 2009, Pages 91-96

  Yim, Su Y ^a,b   Chae, Kab R ^a   Shim, Sun B ^a   Hong, Jin T ^c   Park, Jung Y ^d   Lee, Chung Y ^e   Son, Hong J ^e   Sheen, Yhun Y ^b   Hwang, Dae Youn ^e  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Ewha Womans University   (South Korea)

^c Chungbuk National University   (South Korea)

^d National Fisheries Research and Development Institute (NFRDI)   (South Korea)

^e Pusan National University   (South Korea)

Author keywords

ERK; Secretase; Selenoprotein M; Tau; Transgenic rat

Indexed keywords

ALPHA SECRETASE; BETA SECRETASE; GAMMA SECRETASE; GLUTATHIONE PEROXIDASE; MITOGEN ACTIVATED PROTEIN KINASE; S 5261; SELENOPROTEIN; SODIUM SELENITE; SUPEROXIDE DISMUTASE; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; TRANSGENIC RAT;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; DOWN-REGULATION; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; PHOSPHORYLATION; RATS; RATS, TRANSGENIC; SELENOPROTEINS; SIGNAL TRANSDUCTION; SODIUM SELENITE; TAU PROTEINS;

EID: 67649552785     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000211     Document Type: Article

References (34)

1. Ray WJ, Ashall F and Goate AM: Molecular pathogenesis of sporadic and familial forms of Alzheimer's disease. Mol Med Today 4: 151-157, 1998.
2. Cotman CW and Anderson AJ: A potential role for apoptosis in neurodegeneration and Alzheimer's disease. Mol Neurobiol 10: 19-45, 1995.
3. Boutajangout A, Leroy K, Touchet N, Authelet M, Blanchard V, Tremp G, Pradier L and Brion JP: Increased tau phosphorylation but absence of formation of neurofibrillary tangles in mice double transgenic for human tau and Alzheimer mutant (M146L) presenilin-1. Neurosci Lett 318: 29-33, 2002.
4. Hwang DY, Chae KR, Kang TS, Hwang JH, Lim CH, Kang HK, Goo JS, Lee MR, Lim HJ, Min SH, Cho JY, Hong JT, Song CW, Paik SG, Cho JS and Kim YK: Alterations in behavior, amyloid beta-42, caspase-3, and Cox-2 in mutant PS2 transgenic mouse model of Alzheimer's disease. FASEB J 16: 805-813, 2002.
5. Haass C, Koo EH, Mellon A, Hung AY and Selkoe DJ: Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 357: 500-503, 1992.
6. Murphy MP, Hickman LJ, Eckman CB, Uljon SN, Wang R and Golde TE: gamma-Secretase, evidence for multiple proteolytic activities and influence of membrane positioning of substrate on generation of amyloid beta peptides of varying length. J Biol Chem 274: 11914-11923, 1999.
7. Johnson GV and Stoothoff WH: Tau phosphorylation in neuronal cell function and dysfunction. J Cell Sci 117: 5721-5729, 2004.
8. Shim SB, Lim HJ, Chae KR, Kim CK, Hwang DY, Jee SW, Lee SH, Sin JS, Leem YH, Lee SH, Cho JS, Lee HH, Choi SY and Kim YK: Tau overexpression in transgenic mice induces glycogen synthase kinase 3beta and beta-catenin phosphorylation. Neuroscience 146: 730-740, 2007.
9. Robert M and Mathuranath PS: Tau and tauopathies. Neurol India 55: 11-16, 2007.
10. Wilber CG: Toxicology of selenium: a review. Clin Toxicol 17: 171-230, 1980.
11. Li GX, Hu H, Jiang C, Schuster T and Lü J: Differential involvement of reactive oxygen species in apoptosis induced by two classes of selenium compounds in human prostate cancer cells. Int J Cancer 120: 2034-2043, 2007.
12. Rudolf E, Rudolf K and Cervinka M: Selenium activates p53 and p38 pathways and induces caspase-independent cell death in cervical cancer cells. Cell Biol Toxicol 24: 123-141, 2008.
13. Hu H, Jiang C, Li G and Lü J: PKB/AKT and ERK regulation of caspase-mediated apoptosis by methylseleninic acid in LNCaP prostate cancer cells. Carcinogenesis 26: 1374-1381, 2005.
14. Wang Q, Zhang QG, Wu DN, Yin XH and Zhang GY: Neuroprotection of selenite against ischemic brain injury through negatively regulating early activation of ASK1/JNK cascade via activation of PI3K/AKT pathway. Acta Pharmacol Sin 28: 19-27, 2007.
15. 2, the activity of antioxidant enzymes, and the composition of white blood cells in a transgenic rat. Int J Mol Med 21: 169-179, 2008.
16. Tung YT, Hsu WM, Wang BJ, Wu SY, Yen CT, Hu MK and Liao YF: Sodium selenite inhibits gamma-secretase activity through activation of ERK. Neurosci Lett 440: 38-43, 2008.
17. Kim SK, Park HJ, Hong HS, Baik EJ, Jung MW and Mook-Jung I: ERK1/2 is an endogenous negative regulator of the gamma-secretase activity. FASEB J 20: 157-159, 2006.
18. Smith AM and Picciano MF: Evidence for increased selenium requirement for the rat during pregnancy and lactation. J Nutr 11: 1068-1079, 1986.
19. Yang G, Chen J, Wen Z and Ge K: The role of selenium in Keshan disease. In: Advances in Nutritional Research. Drapper HH (ed). Plenum Press, New York, pp203-231, 1984.
20. Van Rij AM, Thomson CD, McKenzie JM and Robinson MF: Selenium deficiency in total parenteral nutrition. Am J Clin Nutr 32: 2085-2086, 1979.
21. Birringer M, Pilawa S and Flohe L: Trends in selenium biochemistry. Nat Prod Rep 19: 693-718, 2002.
22. Savaskan NE, Brauer AU, Kuhbacher M, Eyupoglu IY, Kyriakopoulos A, Ninnemann O, Behne D and Nitsch R: Selenium deficiency increases susceptibility to glutamate-induced excitotoxicity. FASEB J 17: 112-114, 2003.
23. Jaaro H, Rubinfeld H, Hanoch T and Seger R: Nuclear translocation of mitogen-activated protein kinase kinase (MEK1) in response to mitogenic stimulation. Proc Natl Acad Sci USA 94: 3742-3747, 1997.
24. Seger R, Seger D, Reszka AA, Munar ES, Eldar-Finkelman H, Dobrowolska G, Jensen AM, Campbell JS, Fischer EH and Krebs EG: Overexpression of mitogen-activated protein kinase kinase (MAPKK) and its mutants in NIH 3T3 cells. Evidence that MAPKK involvement in cellular proliferation is regulated by phosphorylation of serine residues in its kinase subdomains VII and VIII. J Biol Chem 269: 25699-25709, 1994.
25. Selkoe DJ: Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81: 741-766, 2001.
26. Iwatsubo T: The gamma-secretase complex: machinery for intramembrane proteolysis. Curr Opin Neurobiol 14: 379-383, 2004.
27. Goedert M, Hasegawa M, Jakes R, Lawler S, Cuenda A and Cohen P: Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases. FEBS Lett 409: 57-62, 1997.
28. Sergeant N, Delacourte A and Buée L: Tau protein as a differential biomarker of tauopathies. Biochim Biophys Acta 1739: 179-197, 2005.
29. Marshall CJ: MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr Opin Genet Dev 4: 82-89, 1994.
30. Waskiewicz AJ and Cooper JA: Mitogen and stress response pathways: MAP kinase cascades and phosphatase regulation in mammals and yeast. Curr Opin Cell Biol 7: 798-805, 1995.
31. Fanger GR, Gerwins P, Widmann C, Jarpe MB and Johnson GL: MEKKs, GCKs, MLKs, PAKs, TAKs, and tpls: upstream regulators of the c-Jun amino-terminal kinases? Curr Opin Genet Dev 7: 67-74, 1997.
32. Lee VM, Goedert M and Trojanowski JQ: Neurodegenerative tauopathies. Annu Rev Neurosci 24: 1121-1159, 2001.
33. Lucas JJ, Hernández F, Gómez-Ramos P, Morán MA, Hen R and Avila J: Decreased nuclear beta-catenin, tau hyper-phosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 20: 27-39, 2001.
34. Lee G, Thangavel R, Sharma VM, Litersky JM, Bhaskar K, Fang SM, Do LH, Andreadis A, Van Hoesen G and Ksiezak-Reding H: Phosphorylation of tau by fyn: implications for Alzheimer's disease. J Neurosci 24: 2304-2312, 2004.